AU2017226830B2 - Titration of cebranopadol - Google Patents

Titration of cebranopadol Download PDF

Info

Publication number
AU2017226830B2
AU2017226830B2 AU2017226830A AU2017226830A AU2017226830B2 AU 2017226830 B2 AU2017226830 B2 AU 2017226830B2 AU 2017226830 A AU2017226830 A AU 2017226830A AU 2017226830 A AU2017226830 A AU 2017226830A AU 2017226830 B2 AU2017226830 B2 AU 2017226830B2
Authority
AU
Australia
Prior art keywords
cebranopadol
daily dose
administration interval
days
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017226830A
Other languages
English (en)
Other versions
AU2017226830A1 (en
Inventor
Roberta BURSI
Chiara PIANA
Shaonan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2017226830A1 publication Critical patent/AU2017226830A1/en
Application granted granted Critical
Publication of AU2017226830B2 publication Critical patent/AU2017226830B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017226830A 2016-02-29 2017-02-28 Titration of cebranopadol Expired - Fee Related AU2017226830B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16157868.7 2016-02-29
EP16157868 2016-02-29
EP16020302 2016-08-11
EP16020302.2 2016-08-11
PCT/EP2017/025034 WO2017148595A1 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Publications (2)

Publication Number Publication Date
AU2017226830A1 AU2017226830A1 (en) 2018-08-16
AU2017226830B2 true AU2017226830B2 (en) 2021-06-24

Family

ID=58185482

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017226830A Expired - Fee Related AU2017226830B2 (en) 2016-02-29 2017-02-28 Titration of cebranopadol

Country Status (10)

Country Link
US (3) US11229625B2 (https=)
EP (1) EP3423054A1 (https=)
JP (2) JP7373904B2 (https=)
CN (2) CN118286209A (https=)
AU (1) AU2017226830B2 (https=)
BR (1) BR112018017167A2 (https=)
CA (1) CA3015420C (https=)
IL (1) IL261133A (https=)
MX (1) MX2018010367A (https=)
WO (1) WO2017148595A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025769A1 (en) * 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
WO2012016698A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2003297073A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DK2600846T3 (en) 2010-08-04 2016-01-11 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM COMPRISING 6'-fluoro- (N-methyl or N, N-dimethyl -) - 4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3 , 4, b] indole] -4-amine
RS54438B1 (sr) 2010-08-04 2016-06-30 Grünenthal GmbH Farmaceutski dozni oblik koji sadrži 6`-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4`,9`-dihidro-3`h-spiro[cikloheksan-1,1`-pirano[3,4,b]indol]-4-amina
NZ604735A (en) 2010-08-04 2014-08-29 Gruenenthal Gmbh Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
PL2649044T3 (pl) 2010-12-08 2018-02-28 Grünenthal GmbH Sposób syntezy podstawionych pochodnych aminocykloheksanonu
CN106939005A (zh) 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
US8614245B2 (en) 2011-07-08 2013-12-24 Gruenenthal Gmbh Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
ES2577861T3 (es) 2011-12-12 2016-07-19 Grünenthal GmbH Proceso para la preparación de (1R,4R)-6'-fluor-(N,N-dimetil- y N-metil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina
US8912343B2 (en) 2011-12-12 2014-12-16 Gruenenthal Gmbh Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
MX353331B (es) 2011-12-12 2018-01-09 Gruenenthal Gmbh Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina.
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
HUE040039T2 (hu) 2014-02-27 2019-02-28 Gruenenthal Gmbh Az 5-fluor-triptofol elõállítására szolgáló eljárás
CA2974578C (en) 2015-01-23 2020-11-17 Grunenthal Gmbh Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
JP7373904B2 (ja) 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025769A1 (en) * 1998-11-02 2000-05-11 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
WO2012016698A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain" Retrieved from the Internet:https://clinicaltrials.gov/ct2/show/record/NCT01725087First Posted 12 November 2012. Retrieved on 2 June 2020 *
COLUZZI, F. et al. "Good practical guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering)" Braz. J. Anesthesiol 2016 May-June, vol. 66, no. 3, pages 310-317 *
SALAT, K. et al. "Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors" Expert Opin. Invest. Drugs (2015) vol. 24, pages 837-844 *

Also Published As

Publication number Publication date
MX2018010367A (es) 2018-12-10
JP7373904B2 (ja) 2023-11-06
JP2021169472A (ja) 2021-10-28
CN109069483A (zh) 2018-12-21
CN118286209A (zh) 2024-07-05
IL261133A (en) 2018-10-31
AU2017226830A1 (en) 2018-08-16
CA3015420A1 (en) 2017-09-08
CA3015420C (en) 2023-09-26
US11229625B2 (en) 2022-01-25
US20220110914A1 (en) 2022-04-14
WO2017148595A1 (en) 2017-09-08
US20250255849A1 (en) 2025-08-14
BR112018017167A2 (pt) 2019-01-02
EP3423054A1 (en) 2019-01-09
JP2019507148A (ja) 2019-03-14
US20180369199A1 (en) 2018-12-27
US12161627B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
US12042494B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
US10786469B2 (en) Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11559523B2 (en) Compositions and methods for treating centrally mediated nausea and vomiting
US11344512B2 (en) Titration of tapentadol
CN114712358A (zh) 用于治疗抑郁症的右美沙芬和安非他酮的组合
JP2025092508A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
KR20200065113A (ko) 항콜린 신경보호 조성물 및 그 방법
US6297286B1 (en) Therapeutic use and formulation
US20250255849A1 (en) Titration of cebranopadol
CN113194950B (zh) 早泄(pe)的治疗和预防
US20180104236A1 (en) Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
HK1233916A1 (en) Titration of tapentadol
HK1204944A1 (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and duloxetine
HK1204944B (en) Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and duloxetine
HK1140940B (en) Titration of tapentadol

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee